DIRS.INFO The most relevant business & tech news

Against this backdrop, hedge funds are placing larger bets by shorting a slew of stocks including C3.ai and U-Haul . In the event that the overall market sell-off stops, however, these stocks could also be in play for a short-squeeze and climb higher. C3.ai has one of the highest short-interest readings on the list of 39.2 million shares through Sept. 15, up from 35.9 million at the end of August. That's up from 7.8 million shares at the conclusion of August. Other stocks that made the list include Intercept Pharmaceuticals , which saw short interest climb 18% from the end of August to the middle of September to 12 million shares.

Persons: shorting, Guess, Italy's Alfasigma, Groupon Organizations: Dow Jones Industrial, Nasdaq, Intercept Pharmaceuticals

Electric vehicle companies Lucid , Fisker and Nikola have had a tough year — and Wall Street expects these stocks have even more downside potential. Nikola, which manufactures electric trucks, has seen its short interest jump nearly 14% to 157.7 million shares, or 27.3% of its float. More than a third of Arcutis Biotherapeutics 's free-float shares have been shorted by Wall Street, or 15.5 million shares. Liver disease treatment company Intercept Pharmaceuticals also saw a 12% jump in short interest, with 9.5 million shares sold short. Below is the full list of the most shorted stocks between July 31 and August 15.

Persons: Nikola, Fisker, Arcutis, scPharmaceuticals, Jerry Durso Organizations: EV, IGM Biosciences, Intercept Pharmaceuticals, U.S . Food, Drug Administration, NASH, Intercept, New York Stock Exchange Locations: FactSet, U.S

☆ US FDA staff flag 'serious' safety risks for Intercept's NASH treatment
▼ + stars: | 2023-05-17 | by ( ) www.reuters.com time to read: +2 min

The U.S. Food and Drug Administration's (FDA) briefing document highlighted increased risk of diabetes and liver injury from using the obeticholic acid (OCA) oral tablets for the treatment of nonalcoholic steatohepatitis (NASH). "During the course of our review, FDA identified modest benefits and serious risks of OCA for treatment of NASH," the staff said in the document and listed increased risk of sludge formation in the gall bladder and imbalance of certain lipids. The staff asked the regulator's panel of outside advisors, who are meeting on Friday, to consider whether the modest benefits from using the drugs for NASH treatment outweigh the serious risks associated with it. The panel's meeting on Friday is the first such meeting for a NASH treatment. However, due to risks of serious liver injury, FDA restricted its usage in 2021 to primary biliary cholangitis patients with advanced cirrhosis, or severe liver scarring.

☆ A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200%
▼ + stars: | 2022-12-19 | by ( Sarah Braner | ) www.businessinsider.com time to read: +2 min

Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NASH. NASH is a serious liver condition that does not have an FDA-approved treatment. Many people don't even know they have it, which is why some people call it a "silent" disease. In a trial of more than 950 patients, 26% of patients taking 80mg and 30% of patients taking 100mg of the drug showed that NASH activity like swelling had been reduced. Pharma hasn't found a way to treat NASH yetThe pharma industry has been watching NASH for a while.

☆ A Chronic Disease Still Waiting for a Drug
▼ + stars: | 2022-09-20 | by ( David Wainer | ) www.wsj.com time to read: +1 min

Drug companies have developed treatments for some of the rarest diseases afflicting a tiny percentage of the population, yet they have failed repeatedly to get a drug on the market for a chronic and increasingly common one. As biotech companies take new shots on goal for the liver disease known as NASH, or nonalcoholic steatohepatitis, investors are understandably reluctant after being burned repeatedly. Take Intercept Pharmaceuticals which at the height of the Wall Street excitement over NASH treatments fetched as much as $462 a share. The stock has since plunged, trading now at just over $17, erasing $6 billion in market value. The biotech’s drug for NASH was rejected by the U.S. Food and Drug Administration in 2020 because of safety concerns, but Intercept is trying again.

Search resuls for: "Intercept Pharmaceuticals"

5 mentions found